Telix Historical Income Statement
| TLX Stock | 25.67 0.07 0.27% |
Historical analysis of Telix Pharmaceuticals income statement accounts such as Total Operating Expenses of 327.1 M, Income Before Tax of 3.2 M, Net Income of 5.5 M or Depreciation And Amortization of 7.1 M can show how well Telix Pharmaceuticals performed in making a profits. Evaluating Telix Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Telix Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Telix Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Telix Pharmaceuticals is a good buy for the upcoming year.
Telix |
About Telix Income Statement Analysis
Telix Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Telix Pharmaceuticals shareholders. The income statement also shows Telix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Telix Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Telix Pharmaceuticals. It is also known as Telix Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most accounts from Telix Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Telix Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Total Revenue is likely to gain to about 521.5 M in 2024, despite the fact that Net Loss is likely to grow to (89 M).
Telix Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Telix Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Telix Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 2.4M | 1.2M | 189K | 406K | 13.1M | 13.8M | |
| Other Operating Expenses | 43.7M | 54.5M | 88.8M | 233.3M | 451.0M | 473.6M | |
| Operating Income | (40.3M) | (49.3M) | (81.2M) | (73.2M) | 51.9M | 54.5M | |
| Ebitda | (36.2M) | (44.9M) | (70.1M) | (92.8M) | 23.0M | 24.1M | |
| Total Operating Expenses | 28.4M | 32.4M | 51.5M | 102.5M | 311.5M | 327.1M | |
| Income Before Tax | (42.8M) | (60.3M) | (99.0M) | (98.6M) | 3.1M | 3.2M | |
| Total Other Income Expense Net | 9.1M | (11M) | (17.8M) | (24.5M) | (48.8M) | (46.4M) | |
| Net Income | (27.9M) | (44.9M) | (80.5M) | (104.1M) | 5.2M | 5.5M | |
| Income Tax Expense | (14.9M) | (15.4M) | (18.5M) | 5.5M | (2.1M) | (2.2M) | |
| Depreciation And Amortization | 4.2M | 4.9M | 5.2M | 5.4M | 6.7M | 7.1M | |
| Selling General Administrative | 6.5M | 7.7M | 34.9M | 77.3M | 79.0M | 82.9M | |
| Total Revenue | 3.5M | 5.2M | 7.6M | 160.1M | 496.7M | 521.5M | |
| Gross Profit | (11.9M) | (16.9M) | (29.8M) | 29.3M | 308.5M | 323.9M | |
| Net Income From Continuing Ops | (27.9M) | (44.9M) | (80.5M) | (104.1M) | 5.2M | 5.5M | |
| Ebit | (40.4M) | (49.8M) | (75.2M) | (98.2M) | 16.2M | 17.0M | |
| Research Development | 21.2M | 23.1M | 34.1M | 57.9M | 128.8M | 135.3M | |
| Cost Of Revenue | 15.4M | 22.1M | 37.4M | 130.8M | 188.2M | 197.6M | |
| Net Income Applicable To Common Shares | (27.9M) | (44.9M) | (80.5M) | (104.1M) | (93.7M) | (89.0M) | |
| Tax Provision | (3.3M) | (3.0M) | 45K | 5.5M | (2.1M) | (2.0M) | |
| Net Interest Income | (2.3M) | (1.1M) | (5.2M) | (6.7M) | (12.8M) | (12.1M) | |
| Interest Income | 2.4M | 67K | 163K | 1K | 1.0M | 626.2K | |
| Selling And Marketing Expenses | 312K | 1.2M | 5.9M | 16.2M | 54.9M | 57.6M | |
| Reconciled Depreciation | 4.2M | 4.9M | 5.2M | 5.4M | 6.7M | 4.2M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.